MTC TRx0014-001 capsules ( DrugBank: - )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
127前頭側頭葉変性症1

127. 前頭側頭葉変性症


臨床試験数 : 90 薬物数 : 87 - (DrugBank : 30) / 標的遺伝子数 : 39 - 標的パスウェイ数 : 88
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2005-005915-13-GB
(EUCTR)
12/07/200610/04/2006An Open Pilot Study of Methlythioninium Chloride (MTC) in Frontotemporal Dementia and Related Dementia Syndromes - Pilot Stidy of MTC in FTD and related dementia syndromesAn Open Pilot Study of Methlythioninium Chloride (MTC) in Frontotemporal Dementia and Related Dementia Syndromes - Pilot Stidy of MTC in FTD and related dementia syndromes Frontotemporal Dementia and related syndromes Prevention and reversal of tau protein aggregation is a novel approach to the treatment of patients with FTD and related syndromes and has the potential for slowing the disease process as well as providing symptomatic improvement in hitherto untreatable, ultimately fatal conditions.
MedDRA version: 8.1;Level: PT;Classification code 10012267
Product Name: Methylthioninium chloride
Product Code: MTC TRx0014-001 capsules
TauRx Therapeutics PTE LtdNULLNot RecruitingFemale: yes
Male: yes
20Phase 2United Kingdom